Literature DB >> 12173036

Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition.

Ilaria Malanchi1, Sandra Caldeira, Maja Krützfeldt, Marianna Giarre, Marianna Alunni-Fabbroni, Massimo Tommasino.   

Abstract

In this study we show that E6 of human papillomavirus has the ability to deregulate the cell cycle G1/S transition. In rodent immortalized fibroblasts (NIH3T3) serum deprivation or over-expression of the cyclin-dependent kinase inhibitors, p16(INK4a) or p27(KIP1), leads to G1 cell cycle arrest. HPV16 E6 overcomes the antiproliferative signals, gaining the ability to drive serum-deprived and p16(INK4a) or p27(KIP1) over-expressing cells into S phase. E6 protein from the benign HPV type 1 displays a similar activity to HPV16 E6 to deregulate the G1/S transition. Thus, this activity appears to be conserved between E6 proteins from non-oncogenic and oncogenic HPV types. Furthermore, we show that HPV16 E6 is not able to circumvent a G1 arrest imposed by pRb mutant in which all CDK phosphorylation sites have been mutated. These data indicate that the viral protein acts upstream of pRb and its mechanism in promoting cell cycle progression is dependent on pRb phosphorylation. In summary, this study describes a novel biological function of HPV E6 and shows that the S phase entry, required for viral DNA replication, is not exclusively controlled by E7, but that E6 also is involved in this event.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173036     DOI: 10.1038/sj.onc.1205617

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  In vitro 3-dimensional tumor model for radiosensitivity of HPV positive OSCC cell lines.

Authors:  Mei Zhang; Barbara Rose; C Soon Lee; Angela M Hong
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

2.  Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38.

Authors:  Wen Dong; Ulrich Kloz; Rosita Accardi; Sandra Caldeira; Wei-Min Tong; Zhao-Qi Wang; Lars Jansen; Matthias Dürst; Bakary S Sylla; Lutz Gissmann; Massimo Tommasino
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins.

Authors:  James D Baleja; Jonathan J Cherry; Zhiguo Liu; Hua Gao; Marc C Nicklaus; Johannes H Voigt; Jason J Chen; Elliot J Androphy
Journal:  Antiviral Res       Date:  2006-04-21       Impact factor: 5.970

4.  PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.

Authors:  Nathaniel Edward Bennett Saidu; Vedrana Filić; Miranda Thomas; Vanessa Sarabia-Vega; Anamaria Đukić; Frane Miljković; Lawrence Banks; Vjekoslav Tomaić
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

5.  Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression.

Authors:  Ilaria Malanchi; Rosita Accardi; Frank Diehl; Anouk Smet; Elliot Androphy; Jörg Hoheisel; Massimo Tommasino
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 6.  The biological properties of E6 and E7 oncoproteins from human papillomaviruses.

Authors:  Raffaella Ghittoni; Rosita Accardi; Uzma Hasan; Tarik Gheit; Bakary Sylla; Massimo Tommasino
Journal:  Virus Genes       Date:  2009-10-17       Impact factor: 2.332

7.  Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Cyclin A1 shows age-related expression in benign tonsils, HPV16-dependent overexpression in HNSCC and predicts lower recurrence rate in HNSCC independently of HPV16.

Authors:  Daniel Weiss; Mario Koopmann; Türker Basel; Claudia Rudack
Journal:  BMC Cancer       Date:  2012-06-19       Impact factor: 4.430

Review 9.  Relevance of Human Papillomaviruses in Head and Neck Cancer-What Remains in 2021 from a Clinician's Point of View?

Authors:  Markus Hoffmann; Elgar Susanne Quabius
Journal:  Viruses       Date:  2021-06-18       Impact factor: 5.048

10.  RNA interference for the treatment of papillomavirus disease.

Authors:  Richa Singhania; Norliana Khairuddin; Daniel Clarke; Nigel Aj McMillan
Journal:  Open Virol J       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.